Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
At SABCS, Presentations Highlight Ongoing Issues with Tamoxifen PGx
December 15, 2010
Although the studies presented at the San Antonio Breast Cancer Symposium did not resolve questions about the role of CYP2D6 genotypes or myriad other factors contributing to variability in tamoxifen metabolism, an oncologist at the Mayo Clinic offered some recommendations as to the types of studies that will be necessary to fill knowledge gaps in the field.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Does Lack of PGx Link in Recent Studies Foreshadow End of CYP2D6 Genotyping for Tamoxifen?
March 14, 2012 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - Mayo Researchers Use Whole-Genome Sequencing, Mouse 'Avatars' to Study Breast Cancer Resistance
April 25, 2012 / Pharmacogenomics Reporter - Mayo Launches Breast Cancer Sequencing, PGx Study
April 9, 2012 / GenomeWeb Daily News - Researchers Combine Metabolism and Transcriptional Profiling to Predict Poor Breast Cancer Outcome
April 20, 2011 / Pharmacogenomics Reporter